Artificial intelligence (AI) company Atomwise has signed an exclusive research collaboration with Sanofi to use its AtomNet platform for computational discovery and research of up to five drug targets. The agreement will see Atomwise receive $20 million from Sanofi to identify, synthesise, and advance lead compounds for up to five targets, which will be exclusive to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!